Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert
July 23, 2010
Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert.
Cameron Durrant, MD, MBA, is the Executive Chairman of the Board of Anavex Life Sciences Corp. ("ANAVEX") (AVXL:OB), a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases (Alzheimer's disease, epilepsy and pain) and various types of cancer. The company has developed a rich portfolio of drug candidates using its proprietary drug discovery SIGMACEPTOR platform and is preparing to enter Phase 1 clinical trials with its lead candidate for the treatment of Alzheimer's in 2010.
Dr. Durrant has a unique entrepreneurial background coupled with almost 20 years of international pharmaceutical and biotech experience. He has held executive positions at both specialty and major global pharmaceutical companies, including Merck & Co., GlaxoSmithKline, Pharmacia Corporation (now part of Pfizer, Inc.) and Johnson & Johnson. He is a serial entrepreneur and CEO.
Dr. Durrant is an experienced media guest (radio, print, online and industry press). He can discuss all aspects of the drug development-commercialization-value creation process (both clinical trials and business considerations), particularly in relation to Alzheimer's disease, other neurological diseases, cancer and infectious diseases. He is highly skilled at making technical topics easy to understand for a general audience.For more information contact
Primoris Group - Media Relations
Website: www.anavex.comClick here to view our Sources Listing: